Literature DB >> 11307592

Penicillium marneffei: types and drug susceptibility.

P Imwidthaya1, K Thipsuvan, A Chaiprasert, S Danchaivijitra, R Sutthent, J Jearanaisilavong.   

Abstract

The PCR fingerprints of 30 Penicillium marneffei isolates from Chiang Rai in Northern Thailand and Bangkok in central Thailand were studied through use of single-nucleotide primers (GACA)4 and the phage M13 core sequence. Discrimination of fingerprint patterns was based on differences in the number of major bands. The P. marneffei isolates were divided into four types, i.e., A, B, C, and D. Type A was found in two isolates from Chiang Rai (6.7%). Types B and C respectively were found in two (6.7%) and one (3.3%) isolates from Bangkok. The predominate type D (83.3%) was found in isolates obtained from Chiang Rai and Bangkok. The PCR fingerprinting method was found to be useful for the epidemiological study of P. marneffei, a dimorphic opportunistic fungus and an emerging pathogen in the HIV pandemic. In vitro drug susceptibility testing by broth macrodilution to four antifungal agents against the yeast form of P. marneffei was performed. The MIC ranges for amphotericin B, fluconazole, itraconazole, and ketoconazole were 0.125-0.5, 4.0-8.0, < 0.032, and < 0.125 microgram/ml respectively.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11307592     DOI: 10.1023/a:1007245226495

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  28 in total

1.  Biotyping of Candida albicans: results of an international collaborative survey.

Authors:  F C Odds; P Auger; P Krogh; A N Neely; E Segal
Journal:  J Clin Microbiol       Date:  1989-07       Impact factor: 5.948

2.  Chronic lymphadenopathy caused by Penicillium marneffei: a condition mimicking tuberculous lymphadenopathy.

Authors:  W C Yuen; Y F Chan; S L Loke; W H Seto; G P Poon; K K Wong
Journal:  Br J Surg       Date:  1986-12       Impact factor: 6.939

Review 3.  DNA fingerprinting of medically important microorganisms by use of PCR.

Authors:  A van Belkum
Journal:  Clin Microbiol Rev       Date:  1994-04       Impact factor: 26.132

4.  Modification and extension of tests for differentiation of Candida species and strains.

Authors:  F C Odds; A B Abbott
Journal:  Sabouraudia       Date:  1983-03

5.  In vitro susceptibility of mycelial and yeast forms of Penicillium marneffei to amphotericin B, fluconazole, 5-fluorocytosine and itraconazole.

Authors:  A S Sekhon; A K Garg; A A Padhye; Z Hamir
Journal:  Eur J Epidemiol       Date:  1993-09       Impact factor: 8.082

6.  Penicillium marneffei osteomyelitis.

Authors:  Y F Chan; K C Woo
Journal:  J Bone Joint Surg Br       Date:  1990-05

7.  Unique oligonucleotide primers in PCR for identification of Cryptococcus neoformans.

Authors:  T G Mitchell; E Z Freedman; T J White; J W Taylor
Journal:  J Clin Microbiol       Date:  1994-01       Impact factor: 5.948

8.  A simple system for the presumptive identification of Candida albicans and differentiation of strains within the species.

Authors:  F C Odds; A B Abbott
Journal:  Sabouraudia       Date:  1980-12

9.  Penicillium marneffei infection in patients infected with human immunodeficiency virus.

Authors:  K Supparatpinyo; S Chiewchanvit; P Hirunsri; C Uthammachai; K E Nelson; T Sirisanthana
Journal:  Clin Infect Dis       Date:  1992-04       Impact factor: 9.079

10.  Isoenzyme biotypes of Candida species.

Authors:  P F Lehmann; B J Kemker; C B Hsiao; S Dev
Journal:  J Clin Microbiol       Date:  1989-11       Impact factor: 5.948

View more
  9 in total

1.  In vitro antifungal-drug susceptibilities of mycelial and yeast forms of Penicillium marneffei isolates in Cambodia.

Authors:  Borann Sar; Sambo Boy; Chantary Keo; Chan Chhaya Ngeth; Narom Prak; Mich Vann; Didier Monchy; Jean Louis Sarthou
Journal:  J Clin Microbiol       Date:  2006-09-13       Impact factor: 5.948

Review 2.  Penicillium marneffei infection and recent advances in the epidemiology and molecular biology aspects.

Authors:  Nongnuch Vanittanakom; Chester R Cooper; Matthew C Fisher; Thira Sirisanthana
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

Review 3.  Talaromycosis (Penicilliosis) Due to Talaromyces (Penicillium) marneffei: Insights into the Clinical Trends of a Major Fungal Disease 60 Years After the Discovery of the Pathogen.

Authors:  Cunwei Cao; Liyan Xi; Vishnu Chaturvedi
Journal:  Mycopathologia       Date:  2019-12       Impact factor: 2.574

4.  Nucleotide sequence-based analysis for determining the molecular epidemiology of Penicillium marneffei.

Authors:  Brent A Lasker
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

5.  Sixty Years from Segretain's Description: What Have We Learned and Should Learn About the Basic Mycology of Talaromyces marneffei?

Authors:  Chi-Ching Tsang; Susanna K P Lau; Patrick C Y Woo
Journal:  Mycopathologia       Date:  2019-12       Impact factor: 2.574

6.  In Vitro Activity of Posaconazole against Talaromyces marneffei by Broth Microdilution and Etest Methods and Comparison to Itraconazole, Voriconazole, and Anidulafungin.

Authors:  Susanna K P Lau; George C S Lo; Clare S K Lam; Wang-Ngai Chow; Antonio H Y Ngan; Alan K L Wu; Dominic N C Tsang; Cindy W S Tse; Tak-Lun Que; Bone S F Tang; Patrick C Y Woo
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

7.  Role of Cannomys badius as a natural animal host of Penicillium marneffei in India.

Authors:  Harish Gugnani; Matthew C Fisher; Anubha Paliwal-Johsi; Nongnuch Vanittanakom; Irabanta Singh; Pratap Singh Yadav
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

8.  Imaging characteristics of disseminated Geosmithia argillacea causing severe diskospondylitis and meningoencephalomyelitis in a dog.

Authors:  Lukas T Kawalilak; Annie V Chen; Greg R Roberts
Journal:  Clin Case Rep       Date:  2015-09-10

Review 9.  Health Risks Associated with Exposure to Filamentous Fungi.

Authors:  Mary Augustina Egbuta; Mulunda Mwanza; Olubukola Oluranti Babalola
Journal:  Int J Environ Res Public Health       Date:  2017-07-04       Impact factor: 3.390

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.